Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
Warm Autoimmune Hemolytic Anemia
About this trial
This is an interventional treatment trial for Warm Autoimmune Hemolytic Anemia focused on measuring warm autoimmune hemolytic anemia, Zanubrutinib
Eligibility Criteria
Inclusion Criteria: Age ≥18 years. Confirmed diagnosis of wAIHA or Evans syndrome, primary or secondary to connective tissue disease. If it is secondary, there are no other treatment indications for systemic involvement of primary connective tissue disease. No response or relapse after glucocorticoid treatment. Baseline liver and kidney function (ALT, AST, Cr) is less than 2 times the normal range. Consent to sign the informed consent form. Exclusion Criteria: Other important organ involvement in connective tissue disease. Uncontrolled infection or bleeding with standard treatment. Active HIV, HCV or HBV infection uncontrolled with standard treatment. Concurrent uncontrolled advanced malignant tumors or lymphoma. The subject is receiving any of the following drugs and has not met the following conditions of stable drug treatment duration at a fixed dose during screening: corticosteroids for at least 4 weeks; iron, vitamin B12 or folic acid for at least 4 weeks; Liver cirrhosis or portal hypertension. Pregnant or lactating women. Participation in other clinical trials within the last 3 months.
Sites / Locations
- Peking Union Medical College Hospital
Arms of the Study
Arm 1
Experimental
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
Zanubrutinib 160mg, orally, twice daily, for a minimum of 3 months For effective patients, continue to use for 2 years after achieving optimal therapeutic effect.